Akebia Names New President and CEO
Akebia appoints new president and CEO.
Akebia Therapeutics, a biopharmaceutical company focused on developing and commercializing small molecules to treat anemia and other diseases, has appointed John P. Butler as its president and CEO. Butler was most recently CEO of Inspiration Biopharmaceuticals and prior to that, held several positions at Genzyme, including president of the Cardiometabolic and Renal Division. As CEO, Butler succeeds Joseph Gardner, PhD, who will remain as an advisor for Akebia and will continue in his role as CEO of the biopharmaceutical company Aerpio Therapeutics. The change will take effect Sept. 16, 2013. With Butler’s appointment, Akebia will establish a corporate office in the Boston area. Akebia's research and development office and activities will remain in Cincinnati.
Source: Akebia Therapeutics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
